MedTrace Logo

Cerebral Bleeding in COVID-19 ARDS Patients on Veno-venous ECMO

NCT04853953 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2021-04-22

No results posted yet for this study

Summary

Critically ill patients with severe acute respiratory distress syndrome (ARDS) sometimes require treatment with veno-venous extracorporeal membrane oxygenation (ECMO) to support gas exchange. To prevent clotting of the ECMO circuit, these patients need to be anticoagulated. This protective anticoagulation also leeds to an increased bleeding risk.

Most critically ill COVID-19 patients suffer from an ARDS and some require ECMO support. However, the optimal strategy and targets for the anticoagulation of these patients remain uncertain. Studies have shown that COVID-19 is associated with endotheliopathy probably leading to procoagulatory effects. On the other hand, the incidence of bleeding complications associated with this endotheliopathy is not clear and remains to be elucidated.

Anticoagulation of COVID-19 patients on ECMO thus poses a challenge for clinicians.

The hypothesis of the current project is that COVID-19 patients with ARDS on ECMO exhibit a higher number of bleeding complications compared to historical control patients with non-COVID-19 ARDS requiring ECMO support.

Conditions

  • Acute Respiratory Distress Syndrome
  • Extracorporeal Membrane Oxygenation Complication
  • Corona Virus Infection

Interventions

OTHER

Incidence of bleeding complications in ARDS patients on veno-venous ECMO

All bleeding complications (especially cerebral bleedings) will be analyzed in the study groups. At the bleeding event, laboratory parameters of coagulation will be collected and the intensity of the ECMO treatment

Sponsors & Collaborators

  • Hannover Medical School

    collaborator OTHER

  • University Hospital, Bonn

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Sascha David, Prof · University Hospital Zurich, Institute of Intensive Care

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2021-07-31
Completion
2021-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04853953 on ClinicalTrials.gov